RT Journal Article SR Electronic T1 Piperine Enhances the Efficacy of TRAIL-based Therapy for Triple-negative Breast Cancer Cells JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 1893 OP 1899 VO 34 IS 4 A1 SHERIF ABDELHAMED A1 SATORU YOKOYAMA A1 ALAA REFAAT A1 KEISUKE OGURA A1 HIDEO YAGITA A1 SURESH AWALE A1 IKUO SAIKI YR 2014 UL http://ar.iiarjournals.org/content/34/4/1893.abstract AB Background/Aim: Triple-negative breast cancer (TNBC) is most the aggressive type of breast cancer and is poorly responsive to endocrine therapeutics; however, one of the most attractive treatments is tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-based therapies. To identify compounds that enhance the efficacy of TRAIL-based therapies, we screened 55 compounds from natural products in combination with TRAIL in TNBC cells. Materials and Methods: Human TNBC cells, MDA-MB-468 and MDA-MB-231, and murine TNBC cells, 4T1, were used. Cell viability, apoptotic cells, and cell cycle were quantified by the WST-1 assay, annexin-V/7-amino-actinomycinD (7-AAD) staining and Propidium iodide (PI) staining, respectively. In vivo effects of piperine were evaluated in the orthotopic-inoculated 4T1-luc mouse model. Results: After screening, we identified piperine as the most potent adjuvant at enhancing the efficacy of TRAIL-based therapies in TNBC cells in vitro and in vivo, which might be mediated through inhibition of survivin and p65 phosphorylation. Conclusion: Piperine may enhance TRAIL-based therapeutics for TNBC.